Gastrointestinal Cancers

Web Exclusives | November 16, 2021
Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone.
Web Exclusives | November 16, 2021
KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy.
Web Exclusives | November 16, 2021
Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile.
Web Exclusives | November 16, 2021
Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer.
Web Exclusives | November 16, 2021
Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement.
Web Exclusives | November 16, 2021
Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer.
Web Exclusives | October 25, 2021
CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer.
Web Exclusives | October 25, 2021
Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer.
Web Exclusives | October 25, 2021
An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma.
Web Exclusives | October 25, 2021
Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study.
Page 1 of 2
Results 1 - 10 of 13

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code